Published in Case Rep Med on April 03, 2012
Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol (2012) 2.12
To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol (2013) 1.04
Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol (2015) 1.02
Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas. Brain Pathol (2014) 0.82
Why does melanoma metastasize into the brain? Genes with pleiotropic effects might be the key. Front Genet (2013) 0.79
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas. Virchows Arch (2012) 0.76
Morphologic spectrum of glial tumors: an increased trend towards oligodendroglial tumors in Pakistan. Int Arch Med (2014) 0.75
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 2.26
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol (2011) 1.90
Optic gliomas in children with neurofibromatosis type 1. J Pediatr (1989) 1.76
BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res (2011) 1.61
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res (2008) 1.47
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol (2001) 1.26
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Neurofibromatosis 2. Curr Opin Neurol (2003) 3.46
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
Neurofibromatosis type 1 revisited. Pediatrics (2009) 3.06
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort study. Lancet Neurol (2012) 2.87
Cumulative diagnostic radiation exposure in children with ventriculoperitoneal shunts: a review. Childs Nerv Syst (2008) 2.79
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell (2008) 2.65
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med (2002) 2.39
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res (2005) 2.02
Surgical management of complex multiloculated hydrocephalus in infants and children. Childs Nerv Syst (2014) 2.02
Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell (2007) 1.92
MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett (2009) 1.92
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer (2010) 1.81
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet (2007) 1.80
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res (2006) 1.80
Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol (2003) 1.72
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res (2007) 1.69
MicroRNA profiling and head and neck cancer. Comp Funct Genomics (2009) 1.68
Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res (2007) 1.65
Nectin-like proteins mediate axon Schwann cell interactions along the internode and are essential for myelination. J Cell Biol (2007) 1.63
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res (2005) 1.63
Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene (2004) 1.61
Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci (2002) 1.59
Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. J Neurosurg Pediatr (2008) 1.59
Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol (2008) 1.59
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology (2005) 1.55
MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics (2009) 1.55
Spinal cord injury without radiologic abnormality in children imaged with magnetic resonance imaging. J Trauma Acute Care Surg (2013) 1.53
Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet (2010) 1.53
Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol (2009) 1.52
Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. Epilepsia (2005) 1.48
Merlin is a potent inhibitor of glioma growth. Cancer Res (2008) 1.47
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res (2008) 1.47
Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia (2004) 1.47
Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia (2009) 1.46
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev (2010) 1.43
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Pediatric neurosurgical injuries associated with all-terrain vehicle accidents: a 10-year experience at St. Louis Children's Hospital. J Neurosurg (2006) 1.42
Molecular pathogenesis of meningiomas. J Neurooncol (2004) 1.42
High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res (2006) 1.42
Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol (2008) 1.41
Orthopedic surgery after selective dorsal rhizotomy for spastic diplegia in relation to ambulatory status and age. J Neurosurg (2005) 1.41
Visual function and optic pathway glioma: a critical response. JAMA Ophthalmol (2013) 1.41
Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol (2005) 1.40
Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis (2007) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol (2002) 1.36
Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis. Mol Cancer Res (2008) 1.35
Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A (2006) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem (2003) 1.35
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A (2004) 1.34
Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother (2009) 1.33
Neurofibromatosis type 1 - a model for nervous system tumour formation? Nat Rev Cancer (2005) 1.33
Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci (2005) 1.33
Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer (2008) 1.33
Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene (2004) 1.32
Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. Neuroimage (2007) 1.32
Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol (2007) 1.31
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res (2005) 1.30
Neurofibromatosis 1. Neurol Clin (2002) 1.30
Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev (2012) 1.30
Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol (2002) 1.29
Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A (2003) 1.28
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol (2012) 1.27
The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. Epilepsia (2007) 1.26
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis (2003) 1.26
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell (2012) 1.26
Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci (2010) 1.25
Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res (2008) 1.24
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia (2008) 1.23
Recent advances in neurofibromatosis type 1. Curr Opin Neurol (2004) 1.23
Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol (2013) 1.22
Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet (2010) 1.21
The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci (2003) 1.21
Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol (2011) 1.20
Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci U S A (2011) 1.20
Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res (2003) 1.20
Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res (2010) 1.20
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res (2011) 1.20
Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet (2010) 1.18
Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J Immunol (2008) 1.18
Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys (2011) 1.16